BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...of RNA epigenetics company Storm Therapeutics Ltd., antibody reagent company Abcam plc and cancer play Chroma Therapeutics Ltd....
...Singapore Bayer AG (Xetra:BAYN), Leverkusen, Germany BioNTech AG, Mainz, Germany Cerevel Therapeutics LLC, Boston, Mass. Chroma Therapeutics Ltd....
BioCentury | Oct 26, 2017
Emerging Company Profile

Taking RNA epigenetics by Storm

...University of Cambridge and a founder of antibody reagent company Abcam plc and cancer company Chroma Therapeutics Ltd....
...CEO: Keith Blundy Patents: None issued Companies and Institutions Mentioned Abcam plc (LSE:ABC), Cambridge, U.K. Chroma Therapeutics Ltd....
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...of the most advanced for an HDAC inhibitor outside of oncology. GSK3117391 is partnered with Chroma Therapeutics Ltd....
...Argonaut Therapeutics Ltd., Oxford, U.K. BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Celgene Corp. (NASDAQ:CELG), Summit, N.J. Chroma Therapeutics Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...£25M ($33.2M) Targeting DNA damage repair pathways Cancer Preclinical Macrophage Pharma Ltd. 2016 Windsor, U.K. Chroma Therapeutics Ltd....
BioCentury | Jan 20, 2017
Company News

Chroma, Macrophage deal

...to tumor-associated macrophages. Chroma Therapeutics Ltd. , Abingdon, U.K. Macrophage Pharma Ltd. , Windsor, U.K. Business: Cancer Alicia Parker Chroma Therapeutics Ltd. Macrophage...
BioCentury | Jan 6, 2017
Product Development

Viral vulnerability

...make cancerous cells vulnerable to antiviral treatment. In November, Viracta acquired lead program VRx-3996 from Chroma Therapeutics Ltd....
...Medicine, Houston, Texas Boston University School of Medicine, Boston, Mass. Cell Medica Ltd., London, U.K. Chroma Therapeutics Ltd....
BioCentury | Dec 22, 2014
Finance

Flexible funding for CRT

...and came in conjunction with the fund's fifth investment, a deal with cancer immunotherapy play Chroma Therapeutics Ltd....
BioCentury | Jun 23, 2014
Clinical News

Tosedostat: Phase II/III started

...21, 2011). Chroma licensed tosedostat from Vernalis. CTI BioPharma Corp . (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Chroma Therapeutics Ltd....
BioCentury | Jan 13, 2014
Clinical News

Tosedostat: Phase II ongoing

...NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Chroma Therapeutics Ltd....
BioCentury | Dec 23, 2013
Clinical News

Tosedostat: Interim Phase II data

...NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Chroma Therapeutics Ltd....
Items per page:
1 - 10 of 61
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...of RNA epigenetics company Storm Therapeutics Ltd., antibody reagent company Abcam plc and cancer play Chroma Therapeutics Ltd....
...Singapore Bayer AG (Xetra:BAYN), Leverkusen, Germany BioNTech AG, Mainz, Germany Cerevel Therapeutics LLC, Boston, Mass. Chroma Therapeutics Ltd....
BioCentury | Oct 26, 2017
Emerging Company Profile

Taking RNA epigenetics by Storm

...University of Cambridge and a founder of antibody reagent company Abcam plc and cancer company Chroma Therapeutics Ltd....
...CEO: Keith Blundy Patents: None issued Companies and Institutions Mentioned Abcam plc (LSE:ABC), Cambridge, U.K. Chroma Therapeutics Ltd....
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...of the most advanced for an HDAC inhibitor outside of oncology. GSK3117391 is partnered with Chroma Therapeutics Ltd....
...Argonaut Therapeutics Ltd., Oxford, U.K. BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Celgene Corp. (NASDAQ:CELG), Summit, N.J. Chroma Therapeutics Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...£25M ($33.2M) Targeting DNA damage repair pathways Cancer Preclinical Macrophage Pharma Ltd. 2016 Windsor, U.K. Chroma Therapeutics Ltd....
BioCentury | Jan 20, 2017
Company News

Chroma, Macrophage deal

...to tumor-associated macrophages. Chroma Therapeutics Ltd. , Abingdon, U.K. Macrophage Pharma Ltd. , Windsor, U.K. Business: Cancer Alicia Parker Chroma Therapeutics Ltd. Macrophage...
BioCentury | Jan 6, 2017
Product Development

Viral vulnerability

...make cancerous cells vulnerable to antiviral treatment. In November, Viracta acquired lead program VRx-3996 from Chroma Therapeutics Ltd....
...Medicine, Houston, Texas Boston University School of Medicine, Boston, Mass. Cell Medica Ltd., London, U.K. Chroma Therapeutics Ltd....
BioCentury | Dec 22, 2014
Finance

Flexible funding for CRT

...and came in conjunction with the fund's fifth investment, a deal with cancer immunotherapy play Chroma Therapeutics Ltd....
BioCentury | Jun 23, 2014
Clinical News

Tosedostat: Phase II/III started

...21, 2011). Chroma licensed tosedostat from Vernalis. CTI BioPharma Corp . (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Chroma Therapeutics Ltd....
BioCentury | Jan 13, 2014
Clinical News

Tosedostat: Phase II ongoing

...NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Chroma Therapeutics Ltd....
BioCentury | Dec 23, 2013
Clinical News

Tosedostat: Interim Phase II data

...NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Chroma Therapeutics Ltd....
Items per page:
1 - 10 of 61